Suksess m/ Bemcentinib
Ny fibrose / lever studie viser positive resultater med Bemcentinib.
Oppdatering kommer iflg artikkel forfatter.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/abstract
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by GAS6 ligand, promotes MASH through the activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition. Methods: Mice were fed chow, or different fat-enriched diets to induce MASH and small molecule AXL kinase inhibition with bemcentinib was evaluated. Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios and cell populations studied using machine learning.Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced pro-inflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T-cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB-NK cells, and increased GzmB+CD8+T-cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue resident memory T-cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signalling and inflammatory response, exhibiting differential cytokine expression in plasma, consistent with liver repair and decreased inflammation. Conclusions: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+T-cell subsets away from an inflammatory phenotype towards fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment.
Bak artikkelen finner vi bl.a. tidligere BGBIO ansatt James B. Lorents.
Les også flg. 6 artikler :
https://www.frontiersin.org/research-topics/54438/inflammatory-responses-on-the-road-from-nash-to-hcc-pathogenic-mechanisms-and-possible-therapeutic-strategies/articles
Oppdatering kommer iflg artikkel forfatter.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/abstract
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by GAS6 ligand, promotes MASH through the activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition. Methods: Mice were fed chow, or different fat-enriched diets to induce MASH and small molecule AXL kinase inhibition with bemcentinib was evaluated. Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios and cell populations studied using machine learning.Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced pro-inflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T-cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB-NK cells, and increased GzmB+CD8+T-cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue resident memory T-cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signalling and inflammatory response, exhibiting differential cytokine expression in plasma, consistent with liver repair and decreased inflammation. Conclusions: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+T-cell subsets away from an inflammatory phenotype towards fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment.
Bak artikkelen finner vi bl.a. tidligere BGBIO ansatt James B. Lorents.
Les også flg. 6 artikler :
https://www.frontiersin.org/research-topics/54438/inflammatory-responses-on-the-road-from-nash-to-hcc-pathogenic-mechanisms-and-possible-therapeutic-strategies/articles
Redigert 17.05.2024 kl 16:37
Du må logge inn for å svare
BioBull
08.05.2024 kl 09:41
9673
Fra Shareville:
"Bemcentinib, en AXL-hemmer, reduserte effektivt pro-inflammatoriske responser i MASH-modeller, selv før fibrose opptrådte. Ved å bruke CyTOF-analyse oppdaget vi en redusert populasjon av Kupffer-celler under MASH samtidig som vi fremmet infiltrasjon av monocytter/makrofager og CD8+ T-celler. Bemcentinib delvis restaurerte Kupffer-celler, reduserte pDC-er og GzmB-NK-celler og økte GzmB+CD8+T-celler og LSEC-er I tillegg forbedret AXL-hemming en undertype av GzmB+CD8+-vevsresidente T-celler preget av CX3CR1-ekspresjon endret det transkriptomiske landskapet assosiert med MASH-progresjon, spesielt i TLR-signalering og inflammatorisk respons, og viser differensiell cytokinekspresjon i plasma, i samsvar med leverreparasjon og redusert betennelse Konklusjoner: Våre funn fremhever sAXL som en biomarkør for å overvåke MASH-progresjon og demonstrerer at AXL-målretting. skiftet levermakrofager og CD8+T-celleundergrupper bort fra en inflammatorisk fenotype mot fibrotisk oppløsning og organheling, og presenterer en lovende strategi for MASH-behandling."
Et lite utdrag av artikkelen "visioninvest" la ut lengre ned her. Dette er utrolig spennende lesning. Husk at dette kommer i TILLEGG til hovedstudien. Bemcentinib kommer til å vise seg nyttig i bruk ved flere forskjellige sykdommer. Den er effektiv, tolereres godt, enkel og skånsom i bruk (tablettform), osv.
"Bemcentinib, en AXL-hemmer, reduserte effektivt pro-inflammatoriske responser i MASH-modeller, selv før fibrose opptrådte. Ved å bruke CyTOF-analyse oppdaget vi en redusert populasjon av Kupffer-celler under MASH samtidig som vi fremmet infiltrasjon av monocytter/makrofager og CD8+ T-celler. Bemcentinib delvis restaurerte Kupffer-celler, reduserte pDC-er og GzmB-NK-celler og økte GzmB+CD8+T-celler og LSEC-er I tillegg forbedret AXL-hemming en undertype av GzmB+CD8+-vevsresidente T-celler preget av CX3CR1-ekspresjon endret det transkriptomiske landskapet assosiert med MASH-progresjon, spesielt i TLR-signalering og inflammatorisk respons, og viser differensiell cytokinekspresjon i plasma, i samsvar med leverreparasjon og redusert betennelse Konklusjoner: Våre funn fremhever sAXL som en biomarkør for å overvåke MASH-progresjon og demonstrerer at AXL-målretting. skiftet levermakrofager og CD8+T-celleundergrupper bort fra en inflammatorisk fenotype mot fibrotisk oppløsning og organheling, og presenterer en lovende strategi for MASH-behandling."
Et lite utdrag av artikkelen "visioninvest" la ut lengre ned her. Dette er utrolig spennende lesning. Husk at dette kommer i TILLEGG til hovedstudien. Bemcentinib kommer til å vise seg nyttig i bruk ved flere forskjellige sykdommer. Den er effektiv, tolereres godt, enkel og skånsom i bruk (tablettform), osv.
BioBull
17.05.2024 kl 16:35
9045
16. mai 2024
We're pleased to inform you that the following article has been published:
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
Sturla Magnus Grøndal • Anna Tutusaus • Loreto Boix • Maria Reig • Magnus Blø • Linn Hodneland • Gro Gausdal • Akil Jackson • Pablo Garcia de Frutos • James Bradley Lorens • Albert Morales • Montserrat Marí
Loop Logo
Frontiers in Immunology
Les alle artiklene her:
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/full
We're pleased to inform you that the following article has been published:
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
Sturla Magnus Grøndal • Anna Tutusaus • Loreto Boix • Maria Reig • Magnus Blø • Linn Hodneland • Gro Gausdal • Akil Jackson • Pablo Garcia de Frutos • James Bradley Lorens • Albert Morales • Montserrat Marí
Loop Logo
Frontiers in Immunology
Les alle artiklene her:
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/full
Pilkastmetoden
18.05.2024 kl 16:43
8617
Disse er dem som direkte er relatert inn i systemet til Bergenbio fra denne artikkelen:
•Linn Hodneland + Gro Gausdal BerGenBio ASA, Bergen, Norway
•Akil Jackson5 BerGenBio Ltd., Oxford, United Kingdom
James Bradley Lorens + Magnus Blø
•Linn Hodneland + Gro Gausdal BerGenBio ASA, Bergen, Norway
•Akil Jackson5 BerGenBio Ltd., Oxford, United Kingdom
James Bradley Lorens + Magnus Blø
elnomi
18.05.2024 kl 17:30
8555
Ja da får vi se om det kommer en børsmelding? hvis det er relevant for BGBIO så må det børsmeldes
tobo581
19.05.2024 kl 08:34
8116
Fortsatt lenge igjen til fase II er sjekket ut. Men dette er positive tegn uansett.
Nicopico
19.05.2024 kl 12:21
7858
Holder på mine aksjer i BGbio i tålmodighet. Har tabbe meg ut på å gi opp å selge aksjer og angret bittert fordi det virket håpløst. Så å vente kan bli Gull 😉
JanH
19.05.2024 kl 12:32
7823
Hva er der positive tegnet her? Her er da ingen nyheter som trenger å børs meldes! Finn heller noe som ee relevant. Det blir litt rart å hente fram noen tilfeldige meldinger på internett.
BioBull
20.05.2024 kl 08:06
7381
Det kan se ut som Bemcentinib fungerer som et «booster» preparat som vil gjøre mange medisiner bedre og mer virkningsfulle.
Jo flere tester som dette - jo bedre.
Et multi-preparat som gjør mange andre medisiner bedre og som også alene kan være med å løse kreft gåten gir godt grunnlag for økt optimisme.
Jo flere tester som dette - jo bedre.
Et multi-preparat som gjør mange andre medisiner bedre og som også alene kan være med å løse kreft gåten gir godt grunnlag for økt optimisme.
kongkveite
20.05.2024 kl 14:37
7087
Om det kan være tilfelle , er i såfall markedet uendelig 👍🥁
Redigert 20.05.2024 kl 15:32
Du må logge inn for å svare
JanH
20.05.2024 kl 21:24
6793
En nyhet om dette, og kursen dobles med en gang.
Jeg tjente foresten en halv månedslønn på to dager i BergenBio, på onsdag og torsdag.
Hvilken aktivta kan man tjene så mye på så kort tid? Dette viser hvor ekstremt lukerativt eierskap i BergenBio er!
Jeg tjente foresten en halv månedslønn på to dager i BergenBio, på onsdag og torsdag.
Hvilken aktivta kan man tjene så mye på så kort tid? Dette viser hvor ekstremt lukerativt eierskap i BergenBio er!
BioBull
21.05.2024 kl 09:51
6424
En nyhet - les selv : mrk. Methods
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/full
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
Sturla Magnus GrndalSturla Magnus Grøndal1†Anna Tutusaus,Anna Tutusaus2,3†Loreto BoixLoreto Boix3Maria ReigMaria Reig3Magnus BlMagnus Blø4Linn HodnelandLinn Hodneland4Gro GausdalGro Gausdal4Akil JacksonAkil Jackson5Pablo Garcia de Frutos,,Pablo Garcia de Frutos2,6,7James Bradley Lorens,*James Bradley Lorens1,4*Albert Morales,*Albert Morales2,3*Montserrat Marí,*Montserrat Marí2,3*
1Department of Biomedicine, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
2Institute of Biomedical Research of Barcelona (IIBB-CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3Barcelona Clinic Liver Cancer Center (BCLC), Hospital Clínic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
4BerGenBio ASA, Bergen, Norway
5BerGenBio Ltd., Oxford, United Kingdom
6Unidad Asociada (IMIM), Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain
7Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain
Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by the GAS6 ligand, promotes MASH through activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition.
Methods: Mice were fed chow or different fat-enriched diets to induce MASH, and small molecule AXL kinase inhibition with bemcentinib was evaluated.
Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios, and cell populations were studied using machine learning.
Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced proinflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB− NK cells, and increased GzmB+CD8+ T cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue-resident memory T cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signaling and inflammatory response, exhibiting differential cytokine expression in the plasma, consistent with liver repair and decreased inflammation.
Conclusion: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+ T-cell subsets away from an inflammatory phenotype toward fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400553/full
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
Sturla Magnus GrndalSturla Magnus Grøndal1†Anna Tutusaus,Anna Tutusaus2,3†Loreto BoixLoreto Boix3Maria ReigMaria Reig3Magnus BlMagnus Blø4Linn HodnelandLinn Hodneland4Gro GausdalGro Gausdal4Akil JacksonAkil Jackson5Pablo Garcia de Frutos,,Pablo Garcia de Frutos2,6,7James Bradley Lorens,*James Bradley Lorens1,4*Albert Morales,*Albert Morales2,3*Montserrat Marí,*Montserrat Marí2,3*
1Department of Biomedicine, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
2Institute of Biomedical Research of Barcelona (IIBB-CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3Barcelona Clinic Liver Cancer Center (BCLC), Hospital Clínic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
4BerGenBio ASA, Bergen, Norway
5BerGenBio Ltd., Oxford, United Kingdom
6Unidad Asociada (IMIM), Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain
7Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain
Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by the GAS6 ligand, promotes MASH through activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition.
Methods: Mice were fed chow or different fat-enriched diets to induce MASH, and small molecule AXL kinase inhibition with bemcentinib was evaluated.
Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios, and cell populations were studied using machine learning.
Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced proinflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB− NK cells, and increased GzmB+CD8+ T cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue-resident memory T cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signaling and inflammatory response, exhibiting differential cytokine expression in the plasma, consistent with liver repair and decreased inflammation.
Conclusion: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+ T-cell subsets away from an inflammatory phenotype toward fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment.
Redigert 21.05.2024 kl 09:53
Du må logge inn for å svare
JanH
27.05.2024 kl 18:25
5312
Utrolig bra dag for oss aksjonærer ! Nå er plutselig alle fornøyde igjen 🙂. Hvor det er det man tjener 4 prosent på en dag ellers liksom ?
Pilkastmetoden
27.05.2024 kl 19:33
5175
Sitat av deg i forrige uke: Jeg tjente foresten en halv månedslønn på to dager i BergenBio, på onsdag og torsdag. .. Og i dag er du påan igjen..
Men ikke glem å ta med de dagene du har tapt penger den siste måneden, eller teller liksom ikke slike fakta for deg?
Men ikke glem å ta med de dagene du har tapt penger den siste måneden, eller teller liksom ikke slike fakta for deg?
Stepping
27.05.2024 kl 21:10
5022
Han treffer klokkerent hver gang så det er ikke noe å bekymre seg for
Føre var
28.05.2024 kl 15:26
4247
Føre var
28.05.2024 kl 15:27
4245
"BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi"
tomjohns
28.05.2024 kl 15:38
4197
En oppsummering av siste del av denne artikkelen med bruk av Copilot:
Martin Olin, administrerende direktør i BerGenBio, uttalte: “Vi er begeistret for å samarbeide med to fremragende partnere for å bringe dette spennende forskningsområdet til pasientene. Denne studien vil ytterligere utvide vår kunnskap om rollen til selektiv AXL-hemming med bemcentinib i lungekreft, vårt område med høyest strategisk fokus.”
Dr. Taverna kommenterte: "Våre data antyder at målrettet behandling av AXL-STAT3-veien med bemcentinib og pacritinib kan forhindre at tumorceller rekrutterer tumorassosierte makrofager og andre aggressive vertsceller til svulstens mikromiljø, noe som forstyrrer tumorvekst og spredning. Forståelsen av denne oppdagelsen kan kaste lys over nye terapeutiske strategier for lungekreft."
Martin Olin, administrerende direktør i BerGenBio, uttalte: “Vi er begeistret for å samarbeide med to fremragende partnere for å bringe dette spennende forskningsområdet til pasientene. Denne studien vil ytterligere utvide vår kunnskap om rollen til selektiv AXL-hemming med bemcentinib i lungekreft, vårt område med høyest strategisk fokus.”
Dr. Taverna kommenterte: "Våre data antyder at målrettet behandling av AXL-STAT3-veien med bemcentinib og pacritinib kan forhindre at tumorceller rekrutterer tumorassosierte makrofager og andre aggressive vertsceller til svulstens mikromiljø, noe som forstyrrer tumorvekst og spredning. Forståelsen av denne oppdagelsen kan kaste lys over nye terapeutiske strategier for lungekreft."
BioBull
28.05.2024 kl 15:44
4167
Ingen tvil om at det har lekket informasjon ut til aktører i forkant av denne meldingen også. Hvorfor klarer ikke BerGenBio å holde kortene tettere til brystet ?
Føre var
28.05.2024 kl 15:47
4154
Opp bare 4%, kan være mer å gå på her.
Redigert 28.05.2024 kl 15:49
Du må logge inn for å svare
Restplassno
28.05.2024 kl 16:45
3990
Tjente en halv månedslønn her i dag jeg, det er ikke verst. Si meg ellers hvor man kan tjene en halv arbeidsinntekt på passivt vis her i landet. Shoutout til JanH som aldri mister troa!
Redigert 28.05.2024 kl 16:46
Du må logge inn for å svare
BioBull
28.05.2024 kl 16:46
3984
Føre var skrev Opp bare 4%, kan være mer å gå på her.
+9 % … blir en uforglemmelig & morsom reise….
Nickhead
28.05.2024 kl 16:55
3945
Vel,la oss si du har en månedslønn.på ca 15000
Så skulle vel det tilsi ca 7500 i redusert tap fra tidligere.
Grattis 😅
Så skulle vel det tilsi ca 7500 i redusert tap fra tidligere.
Grattis 😅
Restplassno
28.05.2024 kl 17:00
3921
Skjønner hva du prøver på, og det er i det hele tatt usympatisk overfor folk med lavere månedsinntekt. Månedsinntekt er relativt og det er ikke den med den høyeste som er den moralske vinneren her. Men takk for innspillet, som alltids et godt forsøk på å fremstå som en drittsekk
Redigert 28.05.2024 kl 17:00
Du må logge inn for å svare
Nickhead
28.05.2024 kl 17:24
3824
Når man er på børs,er det den som sitter igjen med størst månedlig avkastning som er den "moralske" vinner
Mvh en alle tiders hyggelig kar😆
Mvh en alle tiders hyggelig kar😆
Billyjojimbob
28.05.2024 kl 17:53
3699
BioBull skrev +9 % … blir en uforglemmelig & morsom reise….
Restplassno
28.05.2024 kl 20:37
3462
Er det? Når man er på børs - er det den som sitter igjen med størst gevinst, som er den moralske vinner? Måles det i relativ eller absolutt verdi?
BioBull
29.05.2024 kl 07:07
3066
Billyjojimbob skrev https://medwatch.no/nyheter/legemidler_biotek/article17143425.ece
Advancing to the Next Stage of Development
Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update.
Highlights, including post period:
Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a
Site activation of Ph2a in US and Europe proceeding well
Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for inclusion in National Cancer Institute funded study in advanced NSCLC, led by the Mays Cancer Center at the University of Texas Health Science Center at San Antonio
Financial position of NOK 117.3 million at 31 March – strengthened further with gross funding of NOK 138.9 million from warrants exercise in April 2024
Continued reduction of operating expenses from NOK 72.4 million in Q1 2023 to NOK 39.9 million in Q1 2024
Net cash flow of NOK -42.5 million
Martin Olin, Chief Executive Officer of BerGenBio stated:
“1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor prognosis. The total market for this patient group is estimated to be between 4 and 5 billion USD. The initiation of Phase 2a of the study of our lead compound bemcentinib in these patients represents an important milestone for the company. Our clinical progress in the quarter combined with the successful capital raise from the warrants exercise positions BerGenBio to advance a new much needed therapeutic option for these patients with high unmet medical need.”
Presentation and Financial Report
The Q1 2024 Financial report is attached to this stock exchange announcement and the report and the Q1 2024 presentation are available at the Company's website https://www.bergenbio.com/investors/financial-reports.
Webcast details
BerGenBio's senior management team will provide a business update today at 10:00 am CET. The presentation will webcast live. To participate in the webcast, please use the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/
A recording of the webcast will be available at www.bergenbio.com in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) shortly afterwards.
Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update.
Highlights, including post period:
Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a
Site activation of Ph2a in US and Europe proceeding well
Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for inclusion in National Cancer Institute funded study in advanced NSCLC, led by the Mays Cancer Center at the University of Texas Health Science Center at San Antonio
Financial position of NOK 117.3 million at 31 March – strengthened further with gross funding of NOK 138.9 million from warrants exercise in April 2024
Continued reduction of operating expenses from NOK 72.4 million in Q1 2023 to NOK 39.9 million in Q1 2024
Net cash flow of NOK -42.5 million
Martin Olin, Chief Executive Officer of BerGenBio stated:
“1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor prognosis. The total market for this patient group is estimated to be between 4 and 5 billion USD. The initiation of Phase 2a of the study of our lead compound bemcentinib in these patients represents an important milestone for the company. Our clinical progress in the quarter combined with the successful capital raise from the warrants exercise positions BerGenBio to advance a new much needed therapeutic option for these patients with high unmet medical need.”
Presentation and Financial Report
The Q1 2024 Financial report is attached to this stock exchange announcement and the report and the Q1 2024 presentation are available at the Company's website https://www.bergenbio.com/investors/financial-reports.
Webcast details
BerGenBio's senior management team will provide a business update today at 10:00 am CET. The presentation will webcast live. To participate in the webcast, please use the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/
A recording of the webcast will be available at www.bergenbio.com in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) shortly afterwards.
BioBull
29.05.2024 kl 07:19
3005
Imponerende samarbeidspartnere :
https://www.uttyler.edu/academics/colleges-schools/health-science-center/index.php
https://www.sobi.com/sv
https://www.google.com/gasearch?q=swedish%20orphan%20biovitrum%20ab%20marketcap&tbm=&source=sh/x/gs/m2/5
(nesten SEK 100 Milliarder m-cap)
https://www.nordnet.no/market/stocks/16099829-swedish-orphan-biovitrum
https://www.uttyler.edu/academics/colleges-schools/health-science-center/index.php
https://www.sobi.com/sv
https://www.google.com/gasearch?q=swedish%20orphan%20biovitrum%20ab%20marketcap&tbm=&source=sh/x/gs/m2/5
(nesten SEK 100 Milliarder m-cap)
https://www.nordnet.no/market/stocks/16099829-swedish-orphan-biovitrum
Redigert 29.05.2024 kl 07:30
Du må logge inn for å svare
Føre var
29.05.2024 kl 09:07
2666
Her kan det gå fort i svingene:)
Er det svenskene som kjøper?
Er det svenskene som kjøper?
Redigert 29.05.2024 kl 09:08
Du må logge inn for å svare
GulbranGråstein
29.05.2024 kl 10:41
2394
Store ting på gang i BergenBio for tiden, her kan alt skje, og foreløpig ser ting veldig låvende ut.
Jeg har en god følelse for dette selskapet og fremtiden.
Kursmessig er denne alt for lavt om man skal prise inn potensial. Men det kommer etter hvert som resultater legges frem.
Mye på stell her nå, redusert kostnader, samtidig som de har fått inn godt med kapital for videre drift, samt samarbeidspartnere. Dette er og blir veldig spennende både i 2024 og 2025.
Gg
Jeg har en god følelse for dette selskapet og fremtiden.
Kursmessig er denne alt for lavt om man skal prise inn potensial. Men det kommer etter hvert som resultater legges frem.
Mye på stell her nå, redusert kostnader, samtidig som de har fått inn godt med kapital for videre drift, samt samarbeidspartnere. Dette er og blir veldig spennende både i 2024 og 2025.
Gg
kongkveite
29.05.2024 kl 18:12
1987
Bingoen har fremdeles til gode å gå i grønt ved en Q presentasjon.